<DOC>
	<DOCNO>NCT00425802</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor stem cell transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . Also , monoclonal antibody , rituximab , find cancer cell either kill deliver cancer-killing substance without harm normal cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving rituximab transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study side effect well give chemotherapy radiation therapy together rituximab donor stem cell transplant work treat patient B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Chemotherapy , Total-Body Irradiation , Rituximab , Donor Stem Cell Transplant Treating Patients With B-Cell Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall event-free survival 1 year patient B-cell non-Hodgkin 's lymphoma chronic lymphocytic leukemia treat nonmyeloablative conditioning regimen , rituximab , allogeneic hematopoietic stem cell transplantation . Secondary - Determine speed neutrophil platelet recovery patient treat regimen . - Determine incidence speed donor-derived engraftment patient . - Determine incidence severity acute graft versus host disease ( GVHD ) 100 day patient treated regimen . - Determine incidence severity chronic GVHD 1 year patient treat regimen . - Correlate incidence serious infectious complication immune recovery patient treat regimen . - Determine response patient treat regimen . - Determine incidence transplant-related mortality 100 180 day patient . - Determine incidence malignant relapse disease progression 1 2 year patient . - Determine probability overall event-free survival 2 year patient treat regimen . OUTLINE : Patients stratify accord donor type ( HLA-matched relate v HLA-matched unrelated single HLA allele-disparate relate unrelated ) . - Rituximab therapy : Patients receive rituximab IV day -8 -7 day 21 , 28 , 35 , 42 ( + - 2 day ) . - Nonmyeloablative conditioning : Patients receive fludarabine phosphate IV 30 minute day -6 -2 , cyclophosphamide IV day -6 , anti-thymocyte globulin ( ATG ) * IV 4-6 hour day -3 and/or -2 . Patients undergo total-body irradiation day -1 . NOTE : *Patients HLA-matched sibling donor receive ATG . - Allogeneic hematopoietic stem cell transplantation ( HSCT ) : Patients undergo filgrastim ( G-CSF ) -mobilized allogeneic HSCT day 0 . Patients receive filgrastim ( G-CSF ) IV subcutaneously begin day 7 continue blood count recover . - Graft versus host disease prophylaxis : Patients receive cyclosporine IV 2-4 hour orally twice daily day -3 100 follow taper mycophenolate mofetil IV orally twice daily day -3 45 follow taper , absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : CD20positive aggressive Bcell nonHodgkin 's lymphoma ( NHL ) , include follow subtypes : Diffuse large cell lymphoma* , meet 1 follow criterion : Relapsed disease initial therapy , fail mobilize bone marrow involvement therefore suitable autologous stem cell transplantation Highintermediate highrisk secondline , ageadjusted International Prognostic Index score second complete remission ( CR ) partial remission ( PR ) autologous stem cell transplantation Failed prior autologous stem cell transplantation PR good salvage chemotherapy Large cell transformation indolent NHL chronic lymphocytic leukemia ( CLL ) , meet follow criterion : In CR PR large cell component disease salvage chemotherapy autologous stem cell transplantation Mantle cell lymphoma* , meet 1 follow criterion : Highrisk disease ( e.g. , p53 positivity ) first CR PR initial therapy Relapsed disease initial therapy second third CR PR salvage chemotherapy NOTE : *No progressive disease allograft workup CD20positive indolent NHL ( e.g. , follicular lymphoma , small cell lymphoma , marginal zone NHL ) OR CLL Second subsequent progression ( preallograft cytoreduction necessary , CR PR require ) Relapsed disease must biopsyproven Must receive preallograft salvage chemotherapy , include 1 following : Single autologous stem cell transplantation use highdose chemotherapy conditioning within past 120 day At least 2 course intensive combination chemotherapy ( e.g. , RICE [ rituximab , ifosfamide , carboplatin , etoposide ] ) , accord diagnosis , within past 80 day CLL patient receive CAMPATH receive preallograft salvage chemotherapy HLAcompatible relate unrelated donor available HLAmatched ≥ 9/10 A , B , C , DRB1 , DQB1 locus , test high resolution type One allele mismatch allow PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Creatinine &lt; 1.2 mg/mL OR creatinine clearance ≥ 50 mL/min Bilirubin &lt; 2.5 mg/dL AST ALT ≤ 3 time upper limit normal ( unless benign congenital hyperbilirubinemia present ) Spirometry correct DLCO ≥ 50 % normal LVEF ≥ 40 % Albumin ≥ 2.5 g/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active uncontrolled infection , include active infection Aspergillus mold No HIV infection No hepatitis B antibody antigen positivity PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior allogeneic transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>